Still Disease clinical trials at University of California Health

1 research study open to eligible people

PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
open to eligible people ages 6 months to 80 years
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
at UCLA

Last updated: April 16, 2024

PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE